Acorda Neurological Therapy Products and Clinical Research

Bill Dollard

"The most rewarding part of my job is when we hear from patients. You see that what we're doing is really helping them."

Employee since 2002
Technical Operations

More From Bill

As of July 10, 2024, AMPYRA® (dalfampridine), INBRIJA® (levodopa inhalation powder) and ARCUS® technology have been acquired by Merz Therapeutics and will continue to be available to customers through Merz Therapeutics. Click here for more information.

You are now leaving the Acorda.com site. By clicking "Ok", you will be leaving this website (sponsored by Acorda Therapeutics, Inc.) to enter an external and entirely independent website.

Acorda.com provides this link as a service and assumes no responsibility for any information presented on external websites.

Acorda has acquired Biotie Therapies. We invite you to explore www.acorda.com to learn more about our company, including our continued development of BIotie clinical programs for tozadenant, SYN120 and BTT1023. Information regarding transfers of value made to healthcare professionals and healthcare organizations in connection with Biotie’s clinical development programs is also available.

The website uses cookies, which are text files placed on your computer. Some of these are essential to the site’s operation while others analyse how visitors use the site. These cookies are set by default but you can disable them or view more information about how they are used here. By clicking on continue you consent to our use of cookies.